Scarica l'app Stockscreener
10.43
1.70%
-0.12
Dopo l'orario di chiusura:
10.91
0.48
+4.60%
Precedente Chiudi:
$10.55
Aprire:
$10.45
Volume 24 ore:
1.81M
Relative Volume:
1.56
Capitalizzazione di mercato:
$648.31M
Reddito:
$2.00M
Utile/perdita netta:
$-43.51M
Rapporto P/E:
-7.7749
EPS:
-1.3415
Flusso di cassa netto:
$-39.73M
1 W Prestazione:
+8.36%
1M Prestazione:
+32.61%
6M Prestazione:
+101.37%
1 anno Prestazione:
+35.21%
Intervallo 1D:
$10.28
$11.15
Intervallo di 1 settimana:
$9.07
$11.15
Portata 52W:
$4.50
$11.15
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Nome
Sagimet Biosciences Inc
Settore
Industria
Telefono
(650) 561-8600
Indirizzo
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
10.43 | 655.77M | 2.00M | -43.51M | -39.73M | -1.3415 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-26 | Iniziato | Rodman & Renshaw | Buy |
| 2026-02-03 | Iniziato | Guggenheim | Buy |
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2025-08-11 | Iniziato | Wedbush | Outperform |
| 2025-08-07 | Ripresa | H.C. Wainwright | Buy |
| 2025-07-24 | Iniziato | Canaccord Genuity | Buy |
| 2024-12-06 | Iniziato | Oppenheimer | Outperform |
| 2024-11-12 | Iniziato | UBS | Buy |
| 2024-06-28 | Downgrade | Goldman | Buy → Neutral |
| 2024-05-02 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-25 | Iniziato | Leerink Partners | Outperform |
| 2023-08-08 | Iniziato | Goldman | Buy |
| 2023-08-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-08-08 | Iniziato | Piper Sandler | Overweight |
| 2023-08-08 | Iniziato | TD Cowen | Outperform |
Mostra tutto
Sagimet Biosciences Inc Borsa (SGMT) Ultime notizie
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data - marketbeat.com
Dimensional Fund Advisors LP Acquires 135,178 Shares of Sagimet Biosciences Inc. $SGMT - marketbeat.com
Sagimet Biosciences (SGMT) Institutional Ownership 2026 - marketbeat.com
Sagimet Biosciences (NASDAQ:SGMT) Cut to "Sell" at Wall Street Zen - marketbeat.com
SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing? - Stocktwits
SGMT (NASDAQ: SGMT) executive plans 350,987-share stock sale under Form 144 - Stock Titan
Sagimet Biosciences Inc. Series A Common Stock (NASDAQ: SGMT) Stock Price, News & Analysis - kalkine.com.au
Sagimet Biosciences (NASDAQ:SGMT) Given New $29.00 Price Target at Citizens Jmp - marketbeat.com
Citizens raises Sagimet stock price target to $29 on acne drug - Investing.com South Africa
Sagimet Biosciences (SGMT): Balyasny group discloses 5.93% ownership in Schedule 13G - Stock Titan
FDA Approves Sagimet Biosciences' IND for Phase 3 Denifanstat Acne Study - Kalkine Media
Sagimet Biosciences Receives US FDA Clearance for Phase 3 Acne Trial - marketscreener.com
Sagimet Biosciences Inc. (SGMT) Stock Price, News, Quote & History - ca.finance.yahoo.com
Form 8K Sagimet Biosciences Inc For: 13 August By Investing.com - Investing.com Nigeria
Sagimet gets FDA OK for late-stage acne trial (SGMT:NASDAQ) - Seeking Alpha
FDA clears Sagimet’s phase 3 trial for acne treatment denifanstat By Investing.com - Investing.com South Africa
Q4 EPS Estimate for Sagimet Biosciences Decreased by Analyst - marketbeat.com
FDA clears Sagimet’s phase 3 trial for acne treatment denifanstat - Investing.com
FDA clears Sagimet Biosciences to begin Phase 3 trial of denifanstat for acne - Investing.com
Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026 - TradingView
Sagimet Biosciences Announces FDA Clearance of IND for Phase 3 Denifanstat Acne Trial - Quiver Quantitative
Sagimet Plans Acne Trial With About 800 Patients, 450 Expected Adolescents - Stock Titan
Sagimet Biosciences director George Kemble sells $201,146 in shares By Investing.com - Investing.com Canada
Sagimet Biosciences director George Kemble sells $201,146 in shares - Investing.com
Sagimet Biosciences (NASDAQ:SGMT) Director Sells 20,206 Shares of Stock - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
Sagimet Biosciences (NASDAQ:SGMT) Given New $56.00 Price Target at Canaccord Genuity Group - marketbeat.com
Why is Sagimet Biosciences stock climbing today? By Investing.com - Investing.com Australia
Here's Why We're Not At All Concerned With Sagimet Biosciences' (NASDAQ:SGMT) Cash Burn Situation - simplywall.st
Why is Sagimet Biosciences stock climbing today? - Investing.com
Sagimet Biosciences (SGMT) insider plans 20,206-share stock sale after option exercise - Stock Titan
Sagimet Biosciences at Canaccord Genuity conference: acne pivot gains traction - Investing.com Nigeria
Sagimet Biosciences Releases Q2 2026 Financial Results - AlphaStreet
Sagimet Making 'Good Progress' in Bringing Denifanstat to US Patients, Wedbush Securities Says - marketscreener.com
Sagimet Biosciences Q2 Results: EPS misses estimate, losses widen 18.75% YoY - scanx.trade
Sagimet Biosciences (NASDAQ:SGMT) Issues Earnings Results, Beats Estimates By $0.02 EPS - marketbeat.com
Sagimet Biosciences Announces Q2 2026 Financial Results and Updates Investor Presentation - Kalkine Media
Form 8K Sagimet Biosciences Inc For: 11 August By Investing.com - Investing.com Nigeria
Sagimet Reports $14 Million Q2 Net Loss and Phase 3 Acne Trial Plans - Quiver Quantitative
Sagimet Biosciences (SGMT) posts Q2 loss but funds acne pipeline through 2028 - Stock Titan
Sagimet Biosciences (SGMT) boosts cash to $257.6M with 2026 stock sale - Stock Titan
Sagimet Plans Phase 3 Trial for Potential Once-Daily Acne Treatment - Stock Titan
Sagimet Biosciences (SGMT) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Renaissance Technologies LLC Increases Stake in Sagimet Biosciences Inc. $SGMT - marketbeat.com
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
BlackRock, Inc. Expands Stake in Sagimet Biosciences Inc (SGMT) With Strategic Add - GuruFocus
Sagimet: A Look Ahead To Earnings And A Catalyst-Heavy H2 2026 - Seeking Alpha
Sagimet Biosciences (SGMT) to Release Quarterly Earnings on Wednesday - MarketBeat
Exclusive BAC Article: Sagimet Biosciences; China NDA Acceptance Denifanstat For Acne, 2nd Half 2026 U.S. Study Initiation, MASH Drug Combination, And Catalysts (NASDAQ:SGMT) - Seeking Alpha
Sagimet Biosciences to present at Canaccord Gen... - Pluang
Sagimet Biosciences Inc Azioni (SGMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Sagimet Biosciences Inc Azioni (SGMT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kemble George | Director |
Aug 11 '26 |
Option Exercise |
6.36 |
20,206 |
128,510 |
82,367 |
| Kemble George | Director |
Aug 11 '26 |
Sale |
9.95 |
20,206 |
201,147 |
62,161 |
2.20%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):